Cyclacel Pharmaceuticals Inc has a consensus price target of $6.33, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Roth MKM, Brookline Capital, and Roth MKM on May 3, 2024, December 19, 2023, and December 19, 2023. With an average price target of $10.67 between Roth MKM, Brookline Capital, and Roth MKM, there's an implied 422.88% upside for Cyclacel Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
05/03/2024 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | 439.22% | Roth MKM | Jonathan Aschoff | $21 → $11 | Maintains | Buy | Get Alert |
12/19/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
12/19/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | 929.41% | Roth MKM | Jonathan Aschoff | $16 → $21 | Maintains | Buy | Get Alert |
05/25/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | 292.16% | Oppenheimer | Jeff Jones | → $120 | Maintains | Outperform | Get Alert |
03/07/2023 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | 292.16% | Oppenheimer | Jeff Jones | $150 → $120 | Maintains | Outperform | Get Alert |
07/18/2022 | CYCC | Buy Now | Cyclacel Pharmaceuticals | $2.04 | 733.33% | Oppenheimer | Jeff Jones | → $255 | Assumes | → Outperform | Get Alert |
The latest price target for Cyclacel Pharmaceuticals (NASDAQ: CYCC) was reported by Roth MKM on May 3, 2024. The analyst firm set a price target for $11.00 expecting CYCC to rise to within 12 months (a possible 439.22% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Cyclacel Pharmaceuticals (NASDAQ: CYCC) was provided by Roth MKM, and Cyclacel Pharmaceuticals maintained their buy rating.
There is no last upgrade for Cyclacel Pharmaceuticals.
The last downgrade for Cyclacel Pharmaceuticals Inc happened on December 19, 2023 when Brookline Capital changed their price target from N/A to N/A for Cyclacel Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cyclacel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cyclacel Pharmaceuticals was filed on May 3, 2024 so you should expect the next rating to be made available sometime around May 3, 2025.
While ratings are subjective and will change, the latest Cyclacel Pharmaceuticals (CYCC) rating was a maintained with a price target of $21.00 to $11.00. The current price Cyclacel Pharmaceuticals (CYCC) is trading at is $2.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.